skip to main content

Cancer modeling meets human organoid technology

Tuveson, David ; Clevers, Hans

Science (American Association for the Advancement of Science), 2019-06, Vol.364 (6444), p.952-955 [Periódico revisado por pares]

United States: The American Association for the Advancement of Science

Texto completo disponível

Citações Citado por
  • Título:
    Cancer modeling meets human organoid technology
  • Autor: Tuveson, David ; Clevers, Hans
  • Assuntos: Biological Specimen Banks ; Carcinogenesis ; Coculture Techniques ; Gene Editing ; Humans ; Models, Biological ; Neoplasms ; Organoids ; Precision Medicine ; Stem Cells ; Tumor Microenvironment
  • É parte de: Science (American Association for the Advancement of Science), 2019-06, Vol.364 (6444), p.952-955
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Organoids are microscopic self-organizing, three-dimensional structures that are grown from stem cells in vitro. They recapitulate many structural and functional aspects of their in vivo counterpart organs. This versatile technology has led to the development of many novel human cancer models. It is now possible to create indefinitely expanding organoids starting from tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer through the introduction of any combination of cancer gene alterations to normal organoids. When combined with immune cells and fibroblasts, tumor organoids become models for the cancer microenvironment enabling immune-oncology applications. Emerging evidence indicates that organoids can be used to accurately predict drug responses in a personalized treatment setting. Here, we review the current state and future prospects of the rapidly evolving tumor organoid field.
  • Editor: United States: The American Association for the Advancement of Science
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.